 Tuhin Virmani
Concepts (185)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 15 | 2023 | 180 | 9.150 |
Why?
| | Gait Disorders, Neurologic | 11 | 2023 | 36 | 8.090 |
Why?
| | Gait | 9 | 2023 | 98 | 2.520 |
Why?
| | Walking | 4 | 2022 | 110 | 1.610 |
Why?
| | Levodopa | 5 | 2023 | 41 | 1.350 |
Why?
| | Synaptic Vesicles | 6 | 2007 | 19 | 1.210 |
Why?
| | Voice | 1 | 2023 | 21 | 0.940 |
Why?
| | Disease Progression | 3 | 2023 | 915 | 0.870 |
Why?
| | Postural Balance | 2 | 2023 | 61 | 0.840 |
Why?
| | Receptors, Cell Surface | 3 | 2022 | 130 | 0.770 |
Why?
| | Vacuolar Proton-Translocating ATPases | 2 | 2022 | 7 | 0.760 |
Why?
| | Parkinsonian Disorders | 2 | 2022 | 15 | 0.760 |
Why?
| | Freezing Reaction, Cataleptic | 1 | 2018 | 8 | 0.670 |
Why?
| | Foot | 1 | 2018 | 50 | 0.620 |
Why?
| | Humans | 24 | 2023 | 54391 | 0.600 |
Why?
| | RNA Splice Sites | 2 | 2022 | 12 | 0.600 |
Why?
| | Ceruloplasmin | 1 | 2016 | 7 | 0.600 |
Why?
| | Iron Metabolism Disorders | 1 | 2016 | 8 | 0.590 |
Why?
| | Copper | 1 | 2016 | 48 | 0.580 |
Why?
| | Spinal Cord Diseases | 1 | 2016 | 37 | 0.570 |
Why?
| | Zinc | 1 | 2016 | 59 | 0.570 |
Why?
| | Psychomotor Disorders | 1 | 2015 | 3 | 0.550 |
Why?
| | Mental Retardation, X-Linked | 1 | 2015 | 3 | 0.550 |
Why?
| | Neurodegenerative Diseases | 1 | 2016 | 83 | 0.550 |
Why?
| | Ataxia | 1 | 2015 | 23 | 0.540 |
Why?
| | Diplopia | 1 | 2015 | 25 | 0.540 |
Why?
| | Aged | 10 | 2020 | 10060 | 0.530 |
Why?
| | Brain Stem | 1 | 2015 | 46 | 0.530 |
Why?
| | Hippocampus | 6 | 2007 | 242 | 0.520 |
Why?
| | Encephalitis | 1 | 2015 | 48 | 0.520 |
Why?
| | Intellectual Disability | 1 | 2015 | 150 | 0.480 |
Why?
| | Dystonic Disorders | 1 | 2013 | 5 | 0.480 |
Why?
| | Antiparkinson Agents | 1 | 2013 | 21 | 0.470 |
Why?
| | Ocular Motility Disorders | 1 | 2013 | 21 | 0.470 |
Why?
| | Basal Ganglia Diseases | 1 | 2013 | 7 | 0.460 |
Why?
| | Accidental Falls | 3 | 2020 | 98 | 0.460 |
Why?
| | Hypokinesia | 2 | 2023 | 8 | 0.460 |
Why?
| | Chorea | 1 | 2013 | 12 | 0.450 |
Why?
| | Epilepsy | 1 | 2015 | 191 | 0.440 |
Why?
| | Essential Tremor | 1 | 2012 | 10 | 0.440 |
Why?
| | Male | 15 | 2022 | 27347 | 0.430 |
Why?
| | Aging | 1 | 2018 | 784 | 0.430 |
Why?
| | Neocortex | 2 | 2016 | 8 | 0.420 |
Why?
| | Movement | 2 | 2023 | 111 | 0.420 |
Why?
| | Leukoencephalitis, Acute Hemorrhagic | 1 | 2011 | 3 | 0.410 |
Why?
| | Synaptic Transmission | 3 | 2006 | 95 | 0.400 |
Why?
| | Long-Term Synaptic Depression | 2 | 2007 | 2 | 0.360 |
Why?
| | Reproducibility of Results | 2 | 2023 | 1301 | 0.350 |
Why?
| | Presynaptic Terminals | 2 | 2005 | 13 | 0.340 |
Why?
| | Middle Aged | 6 | 2020 | 13082 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 4 | 2016 | 1616 | 0.310 |
Why?
| | Female | 9 | 2020 | 28471 | 0.290 |
Why?
| | Brain | 1 | 2015 | 1392 | 0.290 |
Why?
| | Biological Clocks | 1 | 2006 | 19 | 0.280 |
Why?
| | Thiolester Hydrolases | 1 | 2005 | 7 | 0.280 |
Why?
| | Neuronal Ceroid-Lipofuscinoses | 1 | 2005 | 6 | 0.280 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2005 | 47 | 0.280 |
Why?
| | Neurotransmitter Agents | 1 | 2005 | 38 | 0.270 |
Why?
| | Quality of Life | 2 | 2022 | 924 | 0.260 |
Why?
| | Nerve Net | 1 | 2006 | 74 | 0.260 |
Why?
| | Severity of Illness Index | 2 | 2019 | 1082 | 0.260 |
Why?
| | Calcium-Binding Proteins | 2 | 2005 | 61 | 0.250 |
Why?
| | Phonation | 1 | 2023 | 11 | 0.240 |
Why?
| | Neurons | 3 | 2005 | 486 | 0.240 |
Why?
| | Electromyography | 2 | 2016 | 150 | 0.240 |
Why?
| | Upper Extremity | 1 | 2023 | 50 | 0.230 |
Why?
| | Alternative Splicing | 1 | 2003 | 64 | 0.230 |
Why?
| | Clonazepam | 2 | 2013 | 5 | 0.230 |
Why?
| | GABA Modulators | 2 | 2013 | 12 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 270 | 0.220 |
Why?
| | Siblings | 2 | 2013 | 38 | 0.220 |
Why?
| | Age of Onset | 2 | 2013 | 117 | 0.220 |
Why?
| | Nerve Tissue Proteins | 2 | 2005 | 200 | 0.220 |
Why?
| | Cells, Cultured | 6 | 2006 | 1737 | 0.220 |
Why?
| | Adult | 6 | 2018 | 14207 | 0.220 |
Why?
| | Genetic Variation | 1 | 2003 | 253 | 0.210 |
Why?
| | Young Adult | 3 | 2018 | 4318 | 0.210 |
Why?
| | Synapses | 4 | 2007 | 90 | 0.200 |
Why?
| | Dopamine | 1 | 2022 | 190 | 0.190 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 1141 | 0.180 |
Why?
| | Dopamine Antagonists | 1 | 2018 | 19 | 0.170 |
Why?
| | Phenotype | 1 | 2022 | 819 | 0.170 |
Why?
| | Thiazoles | 1 | 2018 | 61 | 0.170 |
Why?
| | Muscular Diseases | 1 | 2018 | 65 | 0.160 |
Why?
| | Rats, Sprague-Dawley | 4 | 2007 | 1664 | 0.160 |
Why?
| | Piperazines | 1 | 2018 | 115 | 0.160 |
Why?
| | Longitudinal Studies | 1 | 2020 | 742 | 0.150 |
Why?
| | Cranial Nerves | 1 | 2016 | 14 | 0.150 |
Why?
| | Neural Conduction | 1 | 2016 | 45 | 0.150 |
Why?
| | Animals, Newborn | 4 | 2006 | 396 | 0.150 |
Why?
| | Lewy Bodies | 1 | 2016 | 1 | 0.140 |
Why?
| | Rats | 5 | 2007 | 3419 | 0.140 |
Why?
| | tau Proteins | 1 | 2016 | 30 | 0.140 |
Why?
| | Atrophy | 1 | 2015 | 40 | 0.140 |
Why?
| | Corpus Callosum | 1 | 2015 | 28 | 0.130 |
Why?
| | Point Mutation | 1 | 2015 | 92 | 0.130 |
Why?
| | Neuroimaging | 1 | 2015 | 88 | 0.130 |
Why?
| | Age Factors | 1 | 2018 | 1199 | 0.130 |
Why?
| | Cerebellum | 1 | 2015 | 142 | 0.120 |
Why?
| | Time Factors | 3 | 2013 | 3210 | 0.120 |
Why?
| | Group VI Phospholipases A2 | 1 | 2013 | 5 | 0.120 |
Why?
| | Cerebral Cortex | 1 | 2015 | 234 | 0.120 |
Why?
| | Muscle Relaxants, Central | 1 | 2013 | 5 | 0.120 |
Why?
| | Baclofen | 1 | 2013 | 11 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2015 | 234 | 0.120 |
Why?
| | Neurologic Examination | 1 | 2012 | 76 | 0.110 |
Why?
| | Animals | 7 | 2007 | 14409 | 0.100 |
Why?
| | Posture | 1 | 2012 | 79 | 0.100 |
Why?
| | Methylprednisolone | 1 | 2011 | 38 | 0.100 |
Why?
| | Muscle Weakness | 1 | 2011 | 46 | 0.100 |
Why?
| | Headache | 1 | 2011 | 78 | 0.100 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 847 | 0.100 |
Why?
| | Aged, 80 and over | 2 | 2016 | 3431 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 231 | 0.100 |
Why?
| | Cerebral Hemorrhage | 1 | 2011 | 105 | 0.090 |
Why?
| | Alcohol Drinking | 1 | 2012 | 259 | 0.090 |
Why?
| | Macrolides | 2 | 2005 | 17 | 0.090 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2005 | 36 | 0.090 |
Why?
| | Electric Stimulation | 2 | 2006 | 94 | 0.080 |
Why?
| | Electrophysiology | 2 | 2005 | 77 | 0.080 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2005 | 87 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2005 | 927 | 0.080 |
Why?
| | Synaptotagmins | 2 | 2005 | 3 | 0.080 |
Why?
| | Membrane Potentials | 2 | 2005 | 139 | 0.070 |
Why?
| | Muramidase | 1 | 2006 | 17 | 0.070 |
Why?
| | Membrane Fusion | 1 | 2005 | 11 | 0.070 |
Why?
| | Pyridinium Compounds | 1 | 2005 | 17 | 0.070 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2005 | 24 | 0.070 |
Why?
| | Fluorescence | 1 | 2005 | 53 | 0.070 |
Why?
| | Nerve Degeneration | 1 | 2005 | 34 | 0.070 |
Why?
| | Coloring Agents | 1 | 2005 | 84 | 0.070 |
Why?
| | Adaptation, Physiological | 1 | 2006 | 103 | 0.070 |
Why?
| | Receptor, trkB | 1 | 2005 | 11 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2006 | 107 | 0.070 |
Why?
| | Endocytosis | 1 | 2005 | 60 | 0.060 |
Why?
| | Down-Regulation | 1 | 2005 | 388 | 0.060 |
Why?
| | Microscopy, Electron | 1 | 2003 | 97 | 0.060 |
Why?
| | Exons | 1 | 2022 | 105 | 0.050 |
Why?
| | Gene Dosage | 1 | 2022 | 92 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2022 | 124 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2003 | 570 | 0.050 |
Why?
| | Adolescent | 1 | 2013 | 6900 | 0.050 |
Why?
| | Depression | 1 | 2006 | 596 | 0.050 |
Why?
| | Mice | 3 | 2005 | 6428 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2005 | 2001 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2005 | 1647 | 0.040 |
Why?
| | Tourette Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Creatine Kinase | 1 | 2018 | 37 | 0.040 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2018 | 43 | 0.040 |
Why?
| | Haplotypes | 1 | 2016 | 105 | 0.030 |
Why?
| | Mutation | 1 | 2022 | 1504 | 0.030 |
Why?
| | Membrane Proteins | 2 | 2005 | 389 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2005 | 1090 | 0.030 |
Why?
| | Phase Transition | 1 | 2006 | 6 | 0.020 |
Why?
| | Scattering, Radiation | 1 | 2006 | 31 | 0.020 |
Why?
| | Molecular Weight | 1 | 2006 | 100 | 0.020 |
Why?
| | Reaction Time | 1 | 2007 | 227 | 0.020 |
Why?
| | Light | 1 | 2006 | 82 | 0.020 |
Why?
| | Synapsins | 1 | 2005 | 1 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2005 | 7 | 0.020 |
Why?
| | Receptors, Glutamate | 1 | 2005 | 11 | 0.020 |
Why?
| | Synaptotagmin I | 1 | 2005 | 1 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2005 | 19 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2005 | 37 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2005 | 11 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 39 | 0.020 |
Why?
| | Horseradish Peroxidase | 1 | 2005 | 23 | 0.020 |
Why?
| | R-SNARE Proteins | 1 | 2005 | 8 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2005 | 21 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 2005 | 42 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2005 | 82 | 0.020 |
Why?
| | Potassium | 1 | 2005 | 60 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2005 | 148 | 0.020 |
Why?
| | Cell Count | 1 | 2005 | 181 | 0.020 |
Why?
| | Action Potentials | 1 | 2005 | 131 | 0.020 |
Why?
| | Drug Interactions | 1 | 2005 | 206 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2005 | 116 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 151 | 0.020 |
Why?
| | Blotting, Western | 1 | 2005 | 684 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 185 | 0.010 |
Why?
| | Indoles | 1 | 2005 | 289 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 446 | 0.010 |
Why?
| | Models, Biological | 1 | 2005 | 825 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1476 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 1063 | 0.010 |
Why?
|
|
Virmani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|